Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Amerikaanse aandelen  /  ULURU.INC ( ULU) amex

Amerikaanse aandelen« Terug naar discussie overzicht

ULURU.INC ( ULU) amex

Volgen
172 Posts
Pagina: 1 2 3 4 5 6 ... 9 »» | Laatste | Omlaag ↓
  1. welshterrier 5 15 mei 2009 16:11
    komen maandag met cijfers hier
    vandaag van 0,20 naar 0,28
    r.t. nu 0,25 meer dan 2kk omzet

    ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For more information about ULURU Inc., please visit www.uluruinc.com. For more information about Altrazeal(TM), please visit www.altrazeal(TM).com.

  8. [verwijderd] 15 mei 2009 21:42
    quote:

    welshterrier schreef:

    hahaha dank je Roos, was net al 0,30
    staat in de amex, niet bij Rabo

    het wordt toch echt tijd voor de Binck bank Roos :-)))
    jep ik zal volgende week direct even kijken hoe of wat...
    thanks nog voor de tip.
    en tja otc aandelen (wat u vermelde op een ander draadje)zit een groot risico aan, maar kan ook super de andere kant uitschieten...
  10. welshterrier 5 15 mei 2009 22:45
    Press Release Source: ULURU Inc.
    ULURU Inc. Reports First Quarter 2009 Financial Results
    On Friday May 15, 2009, 4:00 pm EDT
    Buzz up! Print Related:ULURU Inc.
    ADDISON, Texas, May 15 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE AMEX: ULU) today announced its financial results for the first quarter ended March 31, 2009. The Company reported a net loss of $3.1 million, or $0.05 per share, compared with a net loss of $1.8 million, or $0.03 per share, for the same period last year. At March 31, 2009, the Company held cash and cash equivalents of $5.1 million, compared with $7.6 million at December 31, 2009.

    Related Quotes
    Symbol Price Change
    ULU 0.29 +0.10


    {"s" : "ulu","k" : "c10,l10,p20,t10","o" : "","j" : ""} Commenting on the financial results Renaat Van den Hooff, President and CEO stated, "The increase in operating expenses continues to be driven by costs associated with our sales and marketing efforts for Altrazeal(TM) and the regulatory and clinical development costs of Altrazeal(TM) Silver and Altrazeal(TM) Collagen." Our recent accomplishments related to the Altrazeal(TM) wound care portfolio include:

    The first published article on Altrazeal(TM) in human use appeared in "International Wound Journal," a peer-reviewed publication (Press release May 5, 2009)
    There were 3 oral presentations and 20 posters published during the first four months of 2009 at several major Wound Care Conferences (DFCon, APWCA, and SAWC).
    We obtained a temporary reimbursement (HCPCS) code for Altrazeal(TM).

    Mr. Van den Hooff continued, "Despite the great clinical results we have experienced, we recognize that the selling cycle is taking longer than we originally expected. This has led us to refocus our sales strategy on specific sites of care. In parallel we have implemented cost improvement measures, including headcount reductions, in order to reduce our operating expenses moving forward. We are also continuing in our efforts to complete the acquisition of York Pharma plc. The strategic importance of creating a larger company with an established revenue base will enable ULURU to accelerate growth and position us to build shareholder value."

    Operating Results

    Revenue for the first quarter of 2009 was $169,000, compared to $256,000 for the first quarter of 2008. The decrease of approximately $87,000 in revenue from the first quarter of 2008 compared to the first quarter of 2009 was due to a $166,000 product order in 2008 for Aphthasol® that did not reoccur in 2009. This revenue decrease was partially offset by increases of $32,000 in Altrazeal product sales, $32,000 in sponsored research, $11,000 in OraDisc(TM) related licensing fees, and $4,000 in Zindaclin® royalties.

    Research and development expenses for the first quarter of 2009 were $775,000, including $42,000 in share-based compensation, compared to $875,000, including $36,000 in share-based compensation, for the first quarter of 2008. The decrease of approximately $100,000 in research and development expenses was primarily due to lower development costs of $169,000 associated with our Altrazeal(TM) related wound care products and decreased costs of $10,000 associated with the clinical studies for Altrazeal(TM) and Altrazeal(TM) Silver. These decreases were partially offset by an increase in regulatory expenses of $88,000 associated with consultants engaged for our regulatory filings for Altrazeal(TM) related products.

    Selling, general and administrative expenses for the first quarter of 2009 were $2.2 million, including $759,000 in share-based compensation, compared to $0.9 million, including $172,000 in share-based compensation, for the first quarter of 2008. The increase of approximately $1.3 million in selling, general and administrative expenses in 2009 was primarily due to costs associated with our sales and marketing efforts of approximately $600,000, distribution services of approximately $120,000, and a net increase of approximately $458,000 in compensation costs. The net increase in compensation cost includes approximately $519,000 of share-based compensation expense after giving effect to certain vesting accelerations of stock options and restricted stock which were partially offset by certain stock option forfeitures and by savings of $77,000 relating to benefit forfeitures pursuant to the Separation Agreement with our former chief executive officer. Other factors affecting the cost increase were additional expenses of $82,000 for legal services associated with our patent filings and $70,000 for legal expense associated with SEC filings, employment matters, and trademark filings.

    Interest and miscellaneous income for the first quarter of 2009 was $15,000 as compared to $125,000 for the first quarter of 2008. The decrease of approximately $110,000 is attributable to a decrease in interest income due to lower cash balances and interest yields in 2009.

    About ULURU Inc.:

    ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit our website at www.altrazeal.com.
  11. welshterrier 5 15 mei 2009 22:53
    cijfers nu al dus, cc as maandag.
    Cijfers zijn iets slechter dan 4 e kwartaal 2008
    volgens Yahoo in de lijn van de verwachtingen.

    Symbol Price Change
    ULU 0.29 +0.10


    {"s" : "ulu","k" : "c10,l10,p20,t10","o" : "","j" : ""} For the fourth quarter of 2008, the Company reported a net loss of $2.9 million, or $0.04 per share
172 Posts
Pagina: 1 2 3 4 5 6 ... 9 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
NX FILTRATION 6,270 +1,42 +29,15%
CM.COM 7,140 +0,19 +2,73%
ArcelorMittal 21,550 +0,53 +2,52%
HEIJMANS KON 24,250 +0,55 +2,32%
PROSUS 33,975 +0,73 +2,20%
SBM Offshore 14,370 +0,22 +1,55%
Fugro 23,040 +0,34 +1,50%
Accsys 0,660 +0,01 +1,38%
Wolters Kluwer 152,650 +2,00 +1,33%
ADYEN NV 1.142,800 +14,60 +1,29%
RANDSTAD NV 44,110 +0,52 +1,19%
TomTom 5,565 +0,07 +1,18%
AZERION 1,636 +0,02 +0,99%
Vopak 40,360 +0,36 +0,90%
SHELL PLC 33,750 +0,22 +0,66%
Arcadis 61,800 +0,40 +0,65%
Aperam 25,780 +0,14 +0,55%
ASR Nederland 45,350 +0,23 +0,51%
Brunel 10,420 +0,04 +0,39%
RENEWI 8,210 +0,03 +0,37%
UNILEVER PLC 52,500 +0,16 +0,31%
Basic-Fit 21,680 +0,06 +0,28%
ING 16,726 +0,05 +0,28%
AALBERTS NV 39,100 +0,10 +0,26%
ASCX 1.269,69 +2,87 +0,23%
AEX 938,12 +2,06 +0,22%
ALLFUNDS GROUP 5,275 +0,01 +0,09%
RELX 42,360 +0,04 +0,09%
Akzo Nobel 57,240 +0,04 +0,07%
KPN 3,637 +0,00 +0,06%
ACOMO 17,720 0,00 0,00%
NSI 19,720 0,00 0,00%
PostNL 1,258 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Pharming 0,784 -0,02 -2,67%
AMG Critical Materials N.V. 16,130 -0,37 -2,24%
EBUSCO HOLDING 1,525 -0,03 -1,99%
IMCD 127,700 -2,45 -1,88%
INPOST 16,140 -0,25 -1,53%
Alfen N.V. 18,585 -0,27 -1,46%
BESI 164,700 -2,00 -1,20%
Heineken 88,400 -1,04 -1,16%
JDE PEET'S 18,260 -0,21 -1,14%
Air France-KLM 8,072 -0,09 -1,13%
FASTNED 16,800 -0,16 -0,94%
NN Group 44,680 -0,38 -0,84%
JUST EAT TAKEAWAY 11,565 -0,10 -0,81%
Kendrion 12,640 -0,10 -0,78%
OCI 23,760 -0,18 -0,75%
ASML 982,100 -7,00 -0,71%
Nedap N.V. 62,800 -0,40 -0,63%
UMG 27,060 -0,17 -0,62%
CTP 16,300 -0,10 -0,61%
ABN AMRO BANK N.V. 15,900 -0,09 -0,59%
Avantium 2,530 -0,02 -0,59%
Fagron 18,480 -0,10 -0,54%
ForFarmers 2,905 -0,02 -0,51%
THEON INTERNAT 12,820 -0,06 -0,47%
TKH 42,800 -0,20 -0,47%
WDP 26,520 -0,12 -0,45%
Eurocommercial Properties 22,900 -0,10 -0,43%
Vastned 24,250 -0,10 -0,41%
DSM FIRMENICH AG 110,250 -0,45 -0,41%
SIGNIFY NV 24,660 -0,10 -0,40%
ASMI 725,200 -2,80 -0,38%
Van Lanschot Kempen NV 39,850 -0,15 -0,37%
Ahold Delhaize 28,750 -0,10 -0,35%
Philips Koninklijke 24,540 -0,08 -0,32%
Sligro 12,340 -0,04 -0,32%
B&S Group SA 4,815 -0,01 -0,31%
EXOR NV 97,750 -0,20 -0,20%
Aegon 5,894 -0,01 -0,20%
Corbion 19,910 -0,04 -0,20%
BAM 4,340 -0,01 -0,18%
Sif Holding 12,680 -0,02 -0,16%
Wereldhave 13,580 -0,02 -0,15%
AMX 887,24 -1,29 -0,15%
Flow Traders 18,790 -0,02 -0,11%
Galapagos 25,000 -0,02 -0,08%
NEEM NU EEN ABONNEMENT OP IEX PREMIUM > NU 3 MAANDEN VOOR SLECHTS €24,95!
vlag naam koers verschil relatief verschil
AEX 938,08 +2,02 +0,22%
AEX GR 3.638,01 +6,40 +0,18%
Germany40^ 18.584,50 +49,94 +0,27%
FTSE 100 8.240,56 +17,22 +0,21%
EURO50 4.998,94 +30,97 +0,62%
US30^ 39.853,20 +94,10 +0,24%
Nasd100^ 20.233,20 +21,50 +0,11%
US500^ 5.592,16 +8,63 +0,15%
Japan225^ 41.277,80 -273,00 -0,66%
VD-NEW 12,71 -0,59 -4,45%
#/^ Index indications calculated real time, zie disclaimer